Twin Capital Management Inc buys $11,064,316 stake in Amgen (AMGN)

Amgen (AMGN) : Twin Capital Management Inc scooped up 9,212 additional shares in Amgen during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Aug 8, 2016. The investment management firm now holds a total of 64,167 shares of Amgen which is valued at $11,064,316.Amgen makes up approximately 0.80% of Twin Capital Management Inc’s portfolio.

Other Hedge Funds, Including , Blair William Coil reduced its stake in AMGN by selling 16,781 shares or 9.19% in the most recent quarter. The Hedge Fund company now holds 165,747 shares of AMGN which is valued at $28,579,755. Amgen makes up approx 0.25% of Blair William Coil’s portfolio.Intrust Bank Na boosted its stake in AMGN in the latest quarter, The investment management firm added 1,997 additional shares and now holds a total of 7,104 shares of Amgen which is valued at $1,232,047. Amgen makes up approx 0.49% of Intrust Bank Na’s portfolio.Oakwood Capital Managementca reduced its stake in AMGN by selling 252 shares or 0.71% in the most recent quarter. The Hedge Fund company now holds 35,026 shares of AMGN which is valued at $5,978,238. Amgen makes up approx 1.51% of Oakwood Capital Managementca’s portfolio.Yhb Investment Advisors boosted its stake in AMGN in the latest quarter, The investment management firm added 2,866 additional shares and now holds a total of 41,258 shares of Amgen which is valued at $6,835,213. Amgen makes up approx 1.45% of Yhb Investment Advisors’s portfolio.Atria Investments reduced its stake in AMGN by selling 175 shares or 2.54% in the most recent quarter. The Hedge Fund company now holds 6,707 shares of AMGN which is valued at $1,076,608. Amgen makes up approx 0.11% of Atria Investments’s portfolio.

Amgen opened for trading at $171.48 and hit $174.72 on the upside on Monday, eventually ending the session at $174.58, with a gain of 0.90% or 1.56 points. The heightened volatility saw the trading volume jump to 27,84,334 shares. Company has a market cap of $130,649 M.

On the company’s financial health, Amgen reported $2.84 EPS for the quarter, beating the analyst consensus estimate by $ 0.10 according to the earnings call on Jul 27, 2016. Analyst had a consensus of $2.74. The company had revenue of $5688.00 million for the quarter, compared to analysts expectations of $5579.33 million. The company’s revenue was up 5.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.57 EPS.

Many Wall Street Analysts have commented on Amgen. Amgen was Initiated by Bernstein to “Mkt Perform” on Jun 29, 2016.

Amgen Inc. (Amgen) is a biotechnology company. The Company is engaged in discovering developing manufacturing and delivering human therapeutics. The Company’s sales and marketing forces are located in the United States and Europe. In the United States it sells its products to pharmaceutical wholesale distributors. The Company also markets certain products directly to consumers through direct-to-consumer print and television advertising as well as through the Internet. Outside the United States the Company sells its products to healthcare providers and/or pharmaceutical wholesale distributors. The Company’s products include Neulasta (pegfilgrastim)/NEUPOGEN (filgrastim) Enbrel (etanercept) XGEVA/Prolia (denosumab) ESAs (erythropoiesis-stimulating agents) Sensipar/Mimpara (cinacalcet) Kyprolis and Evolocumab among others.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *